This is to certify that the project titled “Competitive analysis of “ROSUVASTATIN” & “TELMISARTAN” in the pharmaceutical industry conducted at Coimbatore, Tamilnadu” submitted by MANISH.K.B In partial fulfillment of the requirement for the award of the degree Master of Business Administration (MBA) programme of Sree Narayana Guru Institute of Science and Technology (SNGIST) affiliated to Mahatma Gandhi University during 2005 -2007, is a bonafide record of work done by him under my supervision and guidance and this certificate is not issued to endorse the opinion and results expressed in this report.

Anu Anna AnthonyMs Ranjini…….
Faculty Guide HOD

Dr. Anandakuttan B Unnithan
Director (SNGIST)

ACKNOWLEDGEMENT

I would like to express my sincere thanks to Dr. Anandakuttan B. Unnithan, B.Tech, M.B.A director of Sree Narayana Guru Institute of Science and Technology North Paravur.

I am very thankful to Mrs.Renjini Jaikumar, M.B.A Head of the Department of Management for her kind and help and encouragement.

I wish to express my heartiest thanks to Mrs. Anu Anna Anthony M.B.A, for her valuable guidance suggestion and kind encouragement through the entire phase of the project.

I wish to express my sincere thanks to Mr. FIROZ the area manager and all other staff of Cipla, Coimbatore branch for providing valuable support for the project.

MANISH.K.B

Declaration

I hereby declare that this is a bonafide record of the work done by me in partial fulfillment of the requirement for the award of the degree Master of Business Administration (MBA) of Mahatma Gandhi University and that this report has not been submitted to any university for the award of any degree to the best of my knowledge and belief

N.Paravur MANISH.K.B
Date:30/08/2006

TABLE OF CONTENT

Chapter 1

INDUSTRIAL PROFILE

INDUSTRIAL PROFILE

The Indian Pharmaceutical Industry is expected to undergo phenomenal change when international patent laws will be implemented. India’s domestic pharmaceutical companies have experienced a significant increase in R&D spending to be competitive in the world market. Although the Indian pharmaceutical market is very small and does not have enough funding for drug discovery programs, India has well-educated scientists, a well-established computer industry, and technological know-how for the manufacture of bulk drugs and formulations. The American pharmaceutical industry has played a pioneering role in the development of the drug industry through in-depth, timely, and useful research and bulk manufacturing of drug products. Although the US pharmaceutical industry is enjoying the leadership position, it can no longer be content to focus only on the US, Japanese, and European markets.

Two recent articles that analyzed the Chinese and Hungarian pharmaceutical markets showed that during the 1990s, the Chinese pharmaceutical market experienced overestimated demand and severe under capacity use, and the Hungarian pharmaceutical market suffered setbacks in the same decade and was forced to adopt new strategies to revive the industry (1,2). India, being the second...

YOU MAY ALSO FIND THESE DOCUMENTS HELPFUL

...A. Introduction
Pfizer, US pharmaceutical company is one of the largest pharmaceutical companies in the world. Unfortunately, Pfizer faced challenges by macro-environment forces that affect their sales volume decline dramatically in 2011. PESTEL, Porter’s Five Forces and Industry Lift Cycle frameworks to be applied to analysis the broad macro-environment that affected Pfizer in the pharmaceuticalindustry.
1. PESTEL framework
PESTEL (Appendix I) is classifies into six environmental influences including Political, Economic, Social &amp; Cultural, Technological, Environmental and Legal.
i) Political
* The promotion of pharmaceuticals products in US and patent protection period were direct governed by Food and Drug Administration (FDA). Whereas, self-regulation practiced in New Zealand, UK and Australia are under self-governed by Pharmaceutical Advertising Advisory Board (PAAB) in Canada. Lack of regulatory supervision by PAAB may lead to mis-prescribe to the patients.
* The pressure groups of patients and ageing populations (over 65s) on the healthcare systems. They are lacked of medical insurance and unaffordable to the expensive drugs such as cancer medicines. Subsidization on cancer medicines is strongly demanded.
* The Government’s focus on reducing the healthcare expenditure because the healthcare and medical system were...

...on
IndustryAnalysis of pharmaceuticalindustry.
Prepared for-
Shahnoor
lecturer
Daffodil International University
Prepared by-
Name
ID
Ruhul Amin
113-11-
MD. Tuammel Hossain
113-11-2190
Amina Afrin
113-11-2244
ArshadPharmaceuticalIndustry of Bangladesh
Abstract
Pharmaceutical is the core of Bangladesh’s Healthcare sector, and serves as one of the most important manufacturing industry. With a history since 1950s, the industry has now turned one of the most successful pharmaceuticals manufacturing industry among the developing countries. Presently, the industry meets 97% of local demand and exports to more than 80 countries.
The industry has been experiencing robust growth over the last few years. A local industry supporting drug policy and effective regulatory framework, along with TRIPS relaxations are the key reasons for success of the industry.
While the industry is achieving self-sufficiency, it yet procures 70% of raw materials from abroad. But developments are already taking place, with a number of firms now manufacturing...

...General Environment
The pharmaceuticalindustry has been one of the most profitable and fastest growing industries of the U.S. economy. It provides medicinal and pharmaceutical products that save millions of people from death and disease and also allow ill or sick people to recover and lead normal lives. In today’s market, there are hundreds and thousands of medications available for just about any medical ailment there is: pneumonia, malaria, influenza, STD’s, diabetes, hepatitis, allergies, strokes, cystic fibrosis, psychosis, asthma, neurological disorders, cardiovascular disease, and even cancer.
The pharmaceuticalindustry is regulated not only by laws and statutes, but also by the Food and Drug Administration (FDA) and the Drug Enforcement Agency (DEA). One of the major laws affecting the pharmaceuticalindustry is the patent law. The patent law allows pharmaceutical companies to have exclusive rights to a medication for a certain number of years. This means that no other person or company can copy the drug in hopes of gaining market share. Patent laws help pharmaceutical companies retrieve revenues that are spent in research and development - which are typically in the millions and sometimes billions of dollars range. Other laws, regulations, and acts affecting the pharmaceuticalindustry...

...Background and Business Strategy Section
Major firms of the world pharmaceuticalindustryPharmaceuticalindustry is characterized by high level of concentration. There are about dozen of multinational companies that dominate in industry. Most of companies are not widely diversified and more than 50% of revenues come from sales of pharmaceutical products. There are few companies inindustry that have other large sources of income, for example Johnson & Johnson.
The pharmaceuticalindustry has two distinct functions: research and development (R&D), and manufacturing. The largest and best-known pharmaceutical firms do both functions while some small companies do either of them. Another remarkable characteristic of the pharmaceuticalindustry is its vast investment in R&D to keep product innovation. The high rates of innovation in pharmaceuticalindustry result from high rates of return on investment in R&D also conversely create the incentives necessary to conduct this research. Consumer is sensitive to drug prices. If generic substitute is available it creates high pressure on pricing of product. On other side company is able to charge high premium on patented unique drug.
As a whole, the industry is highly...

...their lives. Today the pharmaceuticalindustry is one of the biggest industries in the United States. The industry experienced a rapid growth rate (in the double digits) in the late 20th century which has now dropped into the single digits (Mullins, 2007). The global demand is driven by factors such as a worldwide increase in elderly population and a rising quality of life in developing nations. Time Magazine listed GenericPharmaceutical Manufacturing as one of the top ten fastest growing industries in the United States for 2012. (Mathews, 2012)
Due to the inherently volatile nature of the industry, it is necessary for companies to constantly adapt through the constant development of effective strategy. Today pharmaceutical companies must not only address finances, but social, legal, and environmental issues as well. In this paper the top ten issues companies face in pharmaceuticals are discussed. They are addressed in an order of descending importance as follows; legal issues, environmental issues, and social issues. When ordering these categories I put myself in the mindset of a potential company investor. Investors are vital to a company’s survival and a potential stockholder is primarily interested in the finances of the company, and its future prospects. Therefore legal action takes precedence above other issues.
Legal:
Legal issues are...

...Security analysis of pharmaceuticalindustry
Shilpa medicare ltd, Ranbaxy, Dr Reedy
[Pick the date]
To Submitted- Prof. Raju Gundala
-------------------------------------------------
By Submitted – Jitendra Singh
-------------------------------------------------
Roll No. – 22, Section – C
-------------------------------------------------
PGDM-IB (2009-11) Batch
-------------------------------------------------
IFIM B SCHOOL Bangalore
-------------------------------------------------
Certificate from IFIM B SCHOOL.
Certificate from the internal faculty
Declaration
I declare that this project report entitled “SECURITY ANALYSIS OF PHARMACETICAL INDUSTRY” is original and bonafide work of my own in the partial fulfillment of the requirements for the award of the Degree of MASTER OF BUSINESS ADMINISTRATION and submitted to the Department of Management, IFIM BUSINESS SCHOOL, Bangalore
The data that has been collected by me is truly authentic and contains true and complete Information.
Jitendra Singh
IFIM B SCHOOL Bangalore
Acknowledgement
Accomplishment of a...

...History of SWOT
In the 1960’s and 70’s, Albert Humphrey is said to have developed this strategic planning tool using data from the top companies in America at the time. A SWOT Analysis looks at the strengths, weaknesses, opportunities and threats that are relevant to an organization in a new venture. A SWOT Analysis is a tool which allows users to look at the direction a company or organization may wish to move towards in the future. A SWOTAnalysis is a useful tool, which in conjunction with others can help make informed decisions.
Definition of SWOT
Many people see SWOT as synonymous with strategic planning. In fact, a SWOT analysis is only one of many tools that can be used in an organization’s strategic planning process. SWOT is short for “Strengths, Weaknesses, Opportunities and Threats”.
By specifying clear objectives and identifying internal and external factors that are either helpful or not, a short and simple SWOT analysis is a useful resource which may be incorporated into an organizations strategic planning model.
Strengths
Internal attributes those are helpful to the organization to achieving its objective
Weaknesses
Internal attributes that are harmful to the organization to achieving its objective
Opportunities
External factors that help the organization achieve its objective
Threats...

...﻿Pharmaceuticalindustry in India
From Wikipedia, the free encyclopedia
The Pharmaceuticalindustry in India is the world's third-largest in terms of volume.[1] According to Department of Pharmaceuticals of the Indian Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticalsindustry between 2008 and September 2009 was US$21.04 billion.[2] While the domestic market was worth US$12.26 billion. The industry holds a market share of $14 billion in the United States. [3]
According to India Brand Equity Foundation, the Indian pharmaceutical market is likely to grow at a compound annual growth rate (CAGR) of 14-17 per cent in between 2012-16.[citation needed] India is now among the top five pharmaceutical emerging markets of the world.[citation needed]
Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006–07 to US$8.7 billion in 2008–09 a combined annual growth rate of 21.25%.[2] According toPricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.[4]
The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970.[5] This patent act removed composition patents from food...